Cue Biopharma logo

Cue Biopharma share price today

(CUE)

Cue Biopharma share price is $0.94 & ₹79.68 as on 14 Dec 2024, 2.30 'hrs' IST

$0.94

-0.1

(-10.05%)

Market is closed - opens 8 PM, 16 Dec 2024

View live Cue Biopharma share price in Dollar and Rupees. Guide to invest in Cue Biopharma from India. Also see the sentimental analysis on Indian investors investing in Cue Biopharma. Get details on the Indian mutual funds that are investing in Cue Biopharma. Get Analyst recommendations and forecasts along with all the Cue Biopharma's financials.

Cue Biopharma share price movements

  • $0.94
    $1.05

    Day's Volatility :10.21%

  • $0.45
    $3.20

    52 Weeks Volatility :85.94%

Cue Biopharma Returns

PeriodCue Biopharma IncSector (Health Care)Index (Russel 2000)
3 Months
66.84%
-9.7%
0.0%
6 Months
-29.85%
-3.4%
0.0%
1 Year
-66.67%
4.2%
0.0%
3 Years
-91.52%
4.2%
-18.1%

Cue Biopharma Key Statistics

in dollars & INR

Previous Close
$1.045
Open
$1.03
Today's High
$1.0469
Today's Low
$0.94
Market Capitalization
$69.1M
Today's Volume
$480.6K
52 Week High
$3.2
52 Week Low
$0.45
Revenue TTM
$8.3M
EBITDA
$-47.7M
Earnings Per Share (EPS)
$-0.87
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-138.87%

How to invest in Cue Biopharma from India?

It is very easy for Indian residents to invest directly in Cue Biopharma from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Cue Biopharma stock in both rupees (INR) and dollars (USD). Search for Cue Biopharma or CUE on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Cue Biopharma or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Cue Biopharma shares which would translate to 0.902 fractional shares of Cue Biopharma as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Cue Biopharma

-45%

Period: Sep 15, 2024 to Dec 14, 2024. Change in 30 Days versus previous period

Search volume for Cue Biopharma on INDmoney from India has reduced in the last 30 days as on Dec 15, 2024. -45% less investors are searching Cue Biopharma in the last 30 days versus the previous period.

Global Institutional Holdings in Cue Biopharma

  • Bleichroeder LP

    7.89%

  • Slate Path Capital LP

    3.79%

  • Vanguard Group Inc

    3.21%

  • BlackRock Inc

    1.19%

  • Geode Capital Management, LLC

    0.80%

  • Robertson Stephens Wealth Management, LLC

    0.76%

Analyst Recommendation on Cue Biopharma

Buy

    88%Buy

    11%Hold

    0%Sell

Based on 9 Wall street analysts offering stock ratings for Cue Biopharma(by analysts ranked 0 to 5 stars)

Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
7
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Cue Biopharma

What analysts predicted

Upside of 282.98%

Current:

$0.94

Target:

$3.60

Insights on Cue Biopharma

  • Price Movement

    In the last 7 days, CUE stock has moved down by -14.5%
  • Increasing Revenue

    Revenue is up for the last 3 quarters, 1.71M → 3.33M (in $), with an average increase of 27.9% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -13.43M → -8.66M (in $), with an average increase of 15.9% per quarter
  • CUE vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 31.6% return, outperforming this stock by 98.1%
  • CUE vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 32.1% return, outperforming this stock by 123.4%
  • Price to Sales

    ForCUE every $1 of sales, investors are willing to pay $5.5, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.9 for every $1 of sales.

Cue Biopharma Financials in INR & Dollars

FY18Y/Y Change
Revenue
$1.1M
-
Net Income
$-39.0M
↑ 67.77%
Net Profit Margin
-3.4K%
-
FY19Y/Y Change
Revenue
$3.5M
↑ 202.64%
Net Income
$-36.7M
↓ 5.86%
Net Profit Margin
-1.1K%
↑ 2350.28%
FY20Y/Y Change
Revenue
$3.2M
↓ 8.78%
Net Income
$-44.8M
↑ 22.04%
Net Profit Margin
-1.4K%
↓ 358.54%
FY21Y/Y Change
Revenue
$14.9M
↑ 373.68%
Net Income
$-44.2M
↓ 1.39%
Net Profit Margin
-295.56%
↑ 1124.23%
FY22Y/Y Change
Revenue
$1.2M
↓ 91.67%
Net Income
$-52.8M
↑ 19.55%
Net Profit Margin
-4.2K%
↓ 3944.31%
FY23Y/Y Change
Revenue
$5.5M
↑ 340.88%
Net Income
$-50.7M
↓ 3.91%
Net Profit Margin
-924.1%
↑ 3315.77%
Q2 FY23Q/Q Change
Revenue
$1.4M
↑ 639.04%
Net Income
$-13.2M
↓ 0.17%
Net Profit Margin
-954.05%
↑ 6109.05%
Q3 FY23Q/Q Change
Revenue
$2.1M
↑ 51.95%
Net Income
$-11.0M
↓ 16.53%
Net Profit Margin
-524.05%
↑ 430.0%
Q4 FY23Q/Q Change
Revenue
$1.8M
↓ 13.29%
Net Income
$-13.4M
↑ 22.07%
Net Profit Margin
-737.73%
↓ 213.68%
Q1 FY24Q/Q Change
Revenue
$1.7M
↓ 5.71%
Net Income
$-12.3M
↓ 8.09%
Net Profit Margin
-719.1%
↑ 18.63%
Q2 FY24Q/Q Change
Revenue
$2.7M
↑ 54.8%
Net Income
$-10.2M
↓ 17.62%
Net Profit Margin
-382.66%
↑ 336.44%
Q3 FY24Q/Q Change
Revenue
$3.3M
↑ 25.51%
Net Income
$-8.7M
↓ 14.86%
Net Profit Margin
-259.59%
↑ 123.07%
FY18Y/Y Change
Profit
$1.1M
↓ 106.05%
FY19Y/Y Change
Profit
$3.5M
↑ 202.64%
FY20Y/Y Change
Profit
$-30.4M
↓ 978.87%
FY21Y/Y Change
Profit
$14.9M
↓ 149.16%
FY22Y/Y Change
Profit
$-560.8K
↓ 103.75%
FY23Y/Y Change
Profit
$-32.6M
↑ 5714.08%
Q2 FY23Q/Q Change
Profit
$534.0K
↓ 177.06%
Q3 FY23Q/Q Change
Profit
$1.2M
↑ 132.77%
Q4 FY23Q/Q Change
Profit
$970.0K
↓ 21.96%
Q1 FY24Q/Q Change
Profit
$868.0K
↓ 10.52%
Q2 FY24Q/Q Change
Profit
$-6.9M
↓ 891.71%
Q3 FY24Q/Q Change
Profit
$3.3M
↓ 148.54%
FY18Y/Y Change
Operating Cash Flow
$-26.4M
↑ 116.63%
Investing Cash Flow
$-20.4M
↑ 1589.18%
Financing Cash Flow
$4.2M
↓ 93.26%
FY19Y/Y Change
Operating Cash Flow
$-30.8M
↑ 16.61%
Investing Cash Flow
$3.4M
↓ 116.93%
Financing Cash Flow
$50.8M
↑ 1114.53%
FY20Y/Y Change
Operating Cash Flow
$-32.5M
↑ 5.51%
Investing Cash Flow
$4.5M
↑ 29.27%
Financing Cash Flow
$58.6M
↑ 15.41%
FY21Y/Y Change
Operating Cash Flow
$-38.8M
↑ 19.52%
Investing Cash Flow
$9.1M
↑ 104.42%
Financing Cash Flow
$19.2M
↓ 67.19%
FY22Y/Y Change
Operating Cash Flow
$-41.8M
↑ 7.64%
Investing Cash Flow
$-24.6M
↓ 370.19%
Financing Cash Flow
$53.7M
↑ 178.99%
Q2 FY23Q/Q Change
Operating Cash Flow
$-10.4M
↓ 4.26%
Investing Cash Flow
$5.0M
↓ 66.67%
Financing Cash Flow
$2.1M
↑ 441.49%

Cue Biopharma Technicals Summary

Sell

Neutral

Buy

Cue Biopharma is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Cue Biopharma Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cue Biopharma Inc
-24.5%
-29.85%
-66.67%
-91.52%
-94.19%
Regeneron Pharmaceuticals, Inc.
-6.54%
-30.04%
-14.05%
15.76%
98.13%
Biontech Se
16.24%
36.11%
16.23%
-57.56%
226.14%
Alnylam Pharmaceuticals, Inc.
-4.84%
56.03%
31.79%
32.76%
110.59%
Vertex Pharmaceuticals Incorporated
-4.18%
-2.1%
14.6%
118.11%
113.09%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cue Biopharma Inc
NA
NA
NA
-0.75
-1.39
-0.52
NA
0.79
Regeneron Pharmaceuticals, Inc.
19.12
19.12
1.15
45.03
0.17
0.07
NA
272.04
Biontech Se
160.8
NA
0.04
-3.11
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
32.84
NA
1.23
0.54
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cue Biopharma Inc
Buy
$69.1M
-94.19%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Buy
$84.9B
98.13%
19.12
33.61%
Biontech Se
Buy
$28.9B
226.14%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Buy
$32.8B
110.59%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Buy
$120.6B
113.09%
32.84
-4.51%

About Cue Biopharma

cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
Organization
Cue Biopharma
Employees
53
CEO
Mr. Daniel R. Passeri J.D., M.Sc.
Industry
Health Technology

Management People of Cue Biopharma

NameTitle
Mr. Daniel R. Passeri J.D., M.Sc.
CEO & Director
Dr. Anish Suri Ph.D.
President & Chief Scientific Officer
Dr. Ronald D. Seidel III, Ph.D.
Co-Founder
Dr. Rodolfo J. Chaparro Ph.D.
Co-Founder & Senior Advisor
Dr. Steven C. Almo Ph.D.
Co-Founder and Chairman of Scientific & Clinical Advisory Board
Mr. Colin G. Sandercock J.D., MSE
Senior VP, General Counsel & Secretary
Dr. Matteo Levisetti M.D.
Chief Medical Officer
Ms. Lucinda Warren
Chief Business Officer

Important FAQs about investing in Cue Biopharma from India :

What is Cue Biopharma share price today?

Cue Biopharma share price today stands at $0.94, Open: $1.03 ; Previous Close: $1.05 ; High: $1.05 ; Low: $0.94 ; 52 Week High: $3.20 ; 52 Week Low: $0.45. The stock opens at $1.03, after a previous close of $1.05. The stock reached a daily high of $1.05 and a low of $0.94, with a 52-week high of $3.20 and a 52-week low of $0.45.

Can Indians buy Cue Biopharma shares?

Yes, Indians can invest in the Cue Biopharma (CUE) from India.

With INDmoney, you can buy Cue Biopharma at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Cue Biopharma at zero transaction cost.

How can I buy Cue Biopharma shares from India?

It is very easy to buy Cue Biopharma from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Cue Biopharma be purchased?

Yes, you can buy fractional shares of Cue Biopharma with INDmoney app.

What are the documents required to start investing in Cue Biopharma stocks?

To start investing in Cue Biopharma, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Cue Biopharma

Today’s highest price of Cue Biopharma (CUE) is $1.05.

Today’s lowest price of Cue Biopharma (CUE) is $0.94.

What is today's market capitalisation of Cue Biopharma

Today's market capitalisation of Cue Biopharma CUE is 69.1M

What is the 52 Week High and Low Range of Cue Biopharma

  • 52 Week High

    $3.20

  • 52 Week Low

    $0.45

How much percentage Cue Biopharma is down from its 52 Week High?

Cue Biopharma (CUE) share price is $0.94. It is down by 70.63% from its 52 Week High price of $3.20.

How much percentage Cue Biopharma is up from its 52 Week low?

Cue Biopharma (CUE) share price is $0.94. It is up by 108.89% from its 52 Week Low price of $0.45.

What are the historical returns of Cue Biopharma?

  • 1 Month Returns

    -24.5%

  • 3 Months Returns

    -29.85%

  • 1 Year Returns

    -66.67%

  • 5 Years Returns

    -94.19%

Who is the Chief Executive Officer (CEO) of Cue Biopharma

Mr. Daniel R. Passeri J.D., M.Sc. is the current Chief Executive Officer (CEO) of Cue Biopharma.